Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Tofacitinib treatment for hair loss may worsen acne.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Ruxolitinib cream may help treat severe hair loss in children.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

A patient with complete hair loss regrew all her hair using tofacitinib.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Tofacitinib helped regrow hair in a lupus patient with alopecia.

A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Tofacitinib helped regrow hair in a woman with alopecia areata.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Upadacitinib may effectively treat alopecia areata without side effects.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.